Literature DB >> 29767815

The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.

Robert Zivadinov1,2, Eleonora Tavazzi3, Jesper Hagemeier3, Ellen Carl3, David Hojnacki4, Channa Kolb4, Bianca Weinstock-Guttman4.   

Abstract

BACKGROUND: Optical coherence tomography (OCT) is a technique that allows for the assessment of retinal nerve fiber layer thickness (RNFLT) and total macular volume (TMV), which reflect neuroaxonal integrity within the retina. As such it has been used in multiple sclerosis (MS) to study neurodegeneration. Glatiramer acetate (GA) is a widely used treatment for MS, which is suggested to have a possible neuroprotective role.
OBJECTIVE: The aim of this study was to assess RFNLT and TMV changes in relapsing-remitting MS (RRMS) patients who started treatment with GA and were followed for a 24-month period.
METHODS: A cohort of 60 RRMS patients and 40 healthy controls (HCs) were imaged with OCT at baseline and follow-up. All subjects also underwent clinical and neurological examination. Measurements were compared between the RRMS patients and HCs as well as between optic neuritis (ON)-affected and ON-unaffected eyes.
RESULTS: At baseline, MS patients showed lower average RNFLT (p = 0.046) and TMV (p = 0.013) when compared with HCs. No significant differences in the evolution of OCT measures were detected over the follow-up between MS patients and HCs. MS patients with both affected and unaffected eyes showed significantly lower average RNFLT, temporal inferior RNFLT, and TMV at baseline, compared with HCs. No significant differences between ON-affected and ON-unaffected eyes in MS patients were detected over the follow-up, except for the nasal superior RNFLT (p = 0.019).
CONCLUSIONS: This study suggests a beneficial role of GA on retinal axonal degeneration in MS, and further confirms the utility of OCT to monitor the neuroprotective effect of disease-modifying treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29767815     DOI: 10.1007/s40263-018-0521-9

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  3 in total

Review 1.  Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.

Authors:  Arielle Kasindi; Dieu-Trang Fuchs; Yosef Koronyo; Altan Rentsendorj; Keith L Black; Maya Koronyo-Hamaoui
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

2.  Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.

Authors:  Jeffrey Lambe; Hunter Risher; Angeliki G Filippatou; Olwen C Murphy; Elias S Sotirchos; Henrik Ehrhardt; Esther Ogbuokiri; Nicole Pellegrini; Brandon Toliver; Nicholas J Luciano; Simidele Davis; Nicholas Fioravante; Ohemaa Kwakyi; Jerry L Prince; Peter A Calabresi; Kathryn C Fitzgerald; Shiv Saidha
Journal:  Neurology       Date:  2021-04-07       Impact factor: 9.910

3.  Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS.

Authors:  Yuyi You; Michael H Barnett; Con Yiannikas; John D E Parratt; Jim G Matthews; Stuart L Graham; Alexander Klistorner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.